SOUTH SAN FRANCISCO, CA--(Marketwire - October 17, 2007) - Theravance, Inc. (NASDAQ: THRX) announced today that Phase 2 results with the investigational compound TD-5108 will be presented today at the American College of Gastroenterology (ACG) Annual Scientific Meeting in Philadelphia, Pennsylvania. The ACG Meeting is focused on clinical updates on gastrointestinal disorders and new or potential new therapies. The TD-5108 results were accepted as a late-breaking presentation.
